Market Overview

Oppenheimer Increases Alimera Sciences PT

Oppenheimer increased its Alimera Sciences (NASDAQ: ALIM) price target from $4 to $7 in a research report published today.

In the report, Oppenheimer stated, "We believe ALIM is leaning toward a commercialization partnership, which would bring in needed capital near-term. We believe ALIM is substantially undervalued on Iluvien's E.U. opportunity."

Shares of Alimera Sciences closed today at $3.94, up 70.56% from Monday's market close.

Posted-In: Analyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (ALIM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters